Schering OTC Claritin Post-Approval Filings To Include Hypospadia Reports
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough's post-approval commitments for OTC Claritin include submitting to FDA reported cases of the birth defect hypospadia following maternal ingestion of loratadine, the company said
You may also be interested in...
Perrigo Licenses Antihistamine Levocetirizine, “Prime” Switch Candidate
Perrigo's licensing agreement with Synthon Pharmaceuticals to market a generic of UCB's antihistamine Xyzal brings the private labeler a "prime example" of an Rx-to-OTC switch candidate. Switch is a "likely scenario" for the allergy drug, Perrigo maintains
Perrigo Licenses Antihistamine Levocetirizine, “Prime” Switch Candidate
Perrigo's licensing agreement with Synthon Pharmaceuticals to market a generic of UCB's antihistamine Xyzal brings the private labeler a "prime example" of an Rx-to-OTC switch candidate. Switch is a "likely scenario" for the allergy drug, Perrigo maintains
Perrigo Licenses Antihistamine Levocetirizine, “Prime” Switch Candidate
Perrigo's licensing agreement with Synthon Pharmaceuticals to market a generic of UCB's antihistamine Xyzal brings the private labeler a "prime example" of an Rx-to-OTC switch candidate. Switch is a "likely scenario" for the allergy drug, Perrigo maintains